// App-Quantinova.ai

: 5D) in Fibrotic Interstitial Lung Disease

Researchers

Presenter

  • A. Tsai

Principal Investigators

  • D. Assayag

  • K. A. Johannson

  • J. Morisset

  • C. D. Fell

  • J. H. Fisher

  • H. Manganas

  • S. Shapera

  • G. P. Cox

  • A. S. Gershon

  • N. Hambly

  • N. Khalil

  • M. Sadatsafavi

  • T. M. To

  • P. Wilcox

  • A. J. Halayko

  • M. R. J. Kolb

  • C. J. Ryerson

Medical Centers

  • Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

  • Montreal University, Montreal, QC, Canada

  • Internal Medicine, University of Calgary, Calgary, AB, Canada

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • South Health Campus, University of Calgary, Calgary, AB, Canada,

  • University of Toronto, Toronto, ON, Canada

  • Medicine, CRCHUM, Montreal, Canada

  • University of Toronto, Toronto, ON, Canada

  • St. Joseph's Healthcare, Hamilton, ON, Canada

  • Institute of Clinical Evaluative Sciences, Toronto, ON, Canada

  • Rheumatology, McMaster University, Hamilton, ON, Canada

  • Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

  • Hospital for Sick Children, Toronto, ON, Canada

  • Internal Medicine, Nephrology, University of Manitoba, Winnipeg, MB, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

  • Extrinsic allergic alveolitis

  • Interstitial lung disease

  • Dyspnea

  • Pulmonary fibrosis

  • Pulmonary alveolar proteinosis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved